A biotechnology company focused on developing therapeutics for systemic amyloidosis.

Attralus

Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Our proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in all systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.

venBio Partners

Redmile Group

Samsara BioCapital

Sarissa Capital Management

Janus Henderson Investors

Logos Capital

Surveyor Capital

Vivo Capital

Attralus 

We’re #hiring a new CMC Project Manager. Apply today or share this post with your network.

We’re #hiring for a Senior Director, Clinical Operations. Apply today or share this post with your network.

Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (#ISA2024)

✳ Read the press release at https://lnkd.in/ebkEEYcV.
 
✳ In total, 16 presentations covering AT-01, AT-02, AT-05 and AT-06 were presented, including three oral presentations, highlighting our pipeline of investigational systemic amyloidosis therapies and diagnostics. 

✳ AT-02, the company’s lead pan-amyloid removal therapeutic candidate, is currently being evaluated in a Phase 1 three-part trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis patients to support its use as an immunotherapy in patients with systemic amyloidosis.

✳ AT-01, the first pan-amyloid diagnostic imaging agent, demonstrated high levels of sensitivity and specificity for detection of cardiac amyloid.

✳ ISA took place in Rochester, MN on 26-30 May 2024. For additional information, visit the ISA 2024 website (https://lnkd.in/eM3S93K5).
 
✳ View conference posters and presentations on our website (https://lnkd.in/eDVZcDxq).

#amyloidosis #rarediseases
 
Liked this post? Want to see more?
 🔔 Sign up for alerts to be notified of our newest posts
 #️⃣ Follow - #Attralus
 🌏 https://www.attralus.com

Attralus continues our strong commitment to patients with systemic amyloidosis at the 2024 International Symposium on #Amyloidosis (ISA). We look forward to seeing you there.
 
✳ 16 presentations covering AT-01, AT-02, AT-05 and AT-06 will be presented, including three oral presentations, highlighting our pipeline of investigational systemic amyloidosis therapies and diagnostics. 

✳ The International Symposium on Amyloidosis (ISA) takes place this year in Rochester, MN from May 26–30, 2024.
 
✳ View posters and presentations on our website following the meeting at https://lnkd.in/eDVZcDxq. 

#amyloidosis #rarediseases #diagnostic
 
Liked this post? Want to see more?
 🔔 Sign up for alerts to be notified of our newest posts
 #️⃣ Follow - #Attralus
 🌏 https://www.attralus.com

We are excited to announce the closing of our $56 million financing. Read the press release at https://lnkd.in/ecAsrj7C

#amyloidosis
__________________________________________________

Liked this post? Want to see more?
🔔 Sign up for alerts to be notified of our newest posts
#️⃣ Follow - #Attralus
🌏 https://www.attralus.com

Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging) 

✳ The Company announced the publication of results from two Attralus-funded investigator-initiated studies of 124I-evuzamitide, the company’s investigational pan-amyloid radiotracer under development for the diagnosis and management of systemic amyloidosis

✳ Read the press release at https://lnkd.in/esQ5FpTV

✳ The manuscripts from Brigham and Women's Hospital and from the The University of Tennessee Graduate School of Medicine were published in the Journal of American College of Cardiology – Cardiovascular Imaging (JACC CV Imaging). 

✳ The two manuscripts were also accompanied by an editorial entitled “Shining a Radiant Light on Cardiac Amyloidosis with Novel 124I-Evuzamitide PET Imaging.” 

✳ All three articles can be found online at https://lnkd.in/eqVy7vRU .

#amyloidosis #rarediseases #diagnostic
__________________________________________________

Liked this post? Want to see more?
🔔 Sign up for alerts to be notified of our newest posts
#️⃣ Follow - #Attralus
🌏 https://www.attralus.com

Metric
Company Name	Attralus
Symbol
MSH ID	COM:ATTRALUS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	31
Website	attralus.com
LinkedIn	attralus
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ATTR

COM:ATTRALUS

Attralus

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue